Search clinical trials for: Docetaxel

Total 2207 results

Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
NCIC Clinical Trials Group

Completed

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

Canada
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Australia
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaborators

Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (ALTER-L024)

Non-small Cell Lung Cancer

China
Samyang Biopharmaceuticals Corporation

Completed

Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer (DOPNP201)

Solid Tumor
National Cancer Center, Korea

Completed

A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma

Stomach Neoplasms

Korea, Republic of
University of Rochester

Completed

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Cervix Neoplasm

United States
National Cancer Center, Korea

Unknown

Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer

Stomach Neoplasms

Korea, Republic of
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Aichi Cancer Center

Completed

Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx

Head and Neck Cancer

Japan
National Taiwan University Hospital

Completed

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

NSCLC

Taiwan
Seagen Inc.

Completed

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma

United States
Sanofi

Completed

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer (Tax-Over)

Ovarian Neoplasms

Turkey
Sanofi

Completed

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

Cancer

United States, France, Canada, Russian Federation, Portugal, Argentina
GlaxoSmithKline

Completed

SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

Solid Tumor Cancer

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Prostate Cancer

France
Sanofi

Completed

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

Spain
Modra Pharmaceuticals

Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States, Germany, Hungary, Poland, Russian Federation, Czechia
European Lung Cancer Working Party

Terminated

Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Carcinoma

Belgium, France, Spain, Greece
National Taiwan University Hospital
Far Eastern Memorial Hospital

Completed

Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin (P-HDFL-DI)

Gastric Cancer

Taiwan
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AstraZeneca

Recruiting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

Prostate Cancer

United States, China, Israel, Korea, Republic of, Canada, Poland, Spain, Belgium, Hungary, Japan, United Kingdom, France, Brazil, Taiwan, Australia, Turkey, Chile, Czechia, India, Mexico, Netherlands, Greece
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Australia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Samsung Medical Center

Completed

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Gastric Adenocarcinoma

Korea, Republic of
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Asan Medical Center
Novartis Pharmaceuticals

Completed

Dovitinib Plus Docetaxel in Gastric Cancer

Gastric Cancer

Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

Advanced Solid Tumors
Pfizer

Withdrawn

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Breast Neoplasms
Swiss Group for Clinical Cancer Research

Completed

Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

Esophageal Cancer

Switzerland
University of Virginia
National Cancer Institute (NCI)

Completed

Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion

Metastatic Cancer

United States
Point Therapeutics

Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small Cell Lung

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Non-small Cell Lung Cancer

China
Instituto Nacional de Cancer, Brazil
Sanofi

Unknown

NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? (NeoSAMBA)

Breast Cancer

Brazil
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Huai'an First People's Hospital
The Second People's Hospital of Huai'an; lian shui county People's Hospital; xuyi... and other collaborators

Completed

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Advanced NSCLC

China
Cristal Therapeutics

Completed

Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer (CINOVA)

Cancer | Ovarian Cancer

Netherlands, Belgium, United Kingdom
Celgene

Completed

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
University of Wisconsin, Madison

Completed

Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Astellas Pharma a/s

Completed

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

Metastatic Castration Resistant Prostate Cancer

Sweden
AmpliMed Corporation

Completed

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Breast Cancer | Prostate Cancer | Non-small Cell Lung Cancer

United States
University College London Hospitals

Completed

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation Carrier

Australia, Israel, United Kingdom, Spain, Sweden, Portugal
Samsung Medical Center

Completed

A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer (DO for AGC)

Gastric Cancer

Korea, Republic of

3

Subscribe